---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-032041"
form_type: "8-K"
ticker: "BCTX"
cik: "0001610820"
company_name: "BriaCell Therapeutics Corp."
filed_at: "2023-09-08T23:59:59+00:00"
generated_at: "2026-06-10T22:11:49.637939+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# BriaCell Phase 2 breast cancer study shows 13.5-month median overall survival vs 6.7-9.8 months literature

## Summary
- Median overall survival 13.5 months in BriaCell's Phase 2 study vs 6.7-9.8 months for similar advanced metastatic breast cancer patients in literature.
- 21 of 29 patients treated since 2022 remain alive, suggesting strong survival benefit with combination regimen.
- No dose limiting toxicities reported; Phase 2 study fully enrolled with 46 heavily pre-treated patients (average 5 prior treatments).
- Combination regimen of Bria-IMT™ with checkpoint inhibitors (pembrolizumab or retifanlimab-dlwr) shows tolerability and efficacy.
- Data supports upcoming pivotal study in advanced breast cancer.

## SEC filing metadata
- accession: 0001493152-23-032041
- form_type: 8-K
- ticker: BCTX
- cik: 0001610820
- company_name: BriaCell Therapeutics Corp.
- filed_at: 2023-09-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1610820/000149315223032041/0001493152-23-032041-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1610820/000149315223032041/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-032041
- JSON: https://secwatch.observer/filing/0001493152-23-032041.json
- Plain text: https://secwatch.observer/filing/0001493152-23-032041.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.